| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/16/2000 | CN1244532A 3,6-aldehyde acetal and enol ether large ring lactone vitamine |
| 02/16/2000 | CN1244529A Novel 8H-thiophene [2,3-b] pyrrolinezine-8-on compound, its preparing method and their medicinal compounds containing them |
| 02/16/2000 | CN1244389A Elemi olefine injecta and its preparation |
| 02/16/2000 | CN1049433C 6,7-modified paclitaxels and medicinal composition containing said compound |
| 02/15/2000 | US6025507 Borneol derivatives, methods of manufacturing them, and their pharmaceutical use |
| 02/15/2000 | US6025474 Isolated nucleic acid molecules coding for tumor rejection antigen precursor mage-3 and uses thereof |
| 02/15/2000 | US6025468 Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides |
| 02/15/2000 | US6025466 With antitumor activity |
| 02/15/2000 | US6025391 Enteric-coated pharmaceutical compositions of mycophenolate |
| 02/15/2000 | US6025388 Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids |
| 02/15/2000 | US6025377 1h-1,2,4-triazole derivative. these compounds can also be used to treat viral infections. |
| 02/15/2000 | US6025372 Somatostatin agonists |
| 02/15/2000 | US6025365 Chelerythrine and radiation combined tumor therapy |
| 02/15/2000 | US6025349 Phenyl.-substituted alkenylcarboguanidides carrying perfluoroalkyl groups, a process for their preparation, their use as a medicament or diagnostic agent, and also a medicament containing them |
| 02/15/2000 | US6025344 Certain dioic acid derivatives useful as NAALADase inhibitors |
| 02/15/2000 | US6025343 Lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs |
| 02/15/2000 | US6025340 Surface expression of enzyme in gene directed prodrug therapy |
| 02/15/2000 | US6025335 L-deoxyribofuranosyl nucleoside phosphodiester dimers where the sugar moiety or at least one of the nucleosides has an l-configuration, cancer and viral infections, in mammals. |
| 02/15/2000 | US6025334 Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compositions thereof |
| 02/15/2000 | US6025331 Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis |
| 02/15/2000 | US6025328 Antitumor agents |
| 02/15/2000 | US6025204 Diagnostic method for detection of placental-derived prostate growth factors |
| 02/15/2000 | US6025195 Liver-specific adenovirus expression vector |
| 02/15/2000 | US6025180 Asp1 |
| 02/15/2000 | US6025166 Human trk receptors and neurotrophic factor inhibitors |
| 02/15/2000 | US6025150 Methods and compositions for wound healing |
| 02/15/2000 | US6025142 Hydrophobic u-PAR binding site |
| 02/15/2000 | US6024955 Peptide with amino acid sequences |
| 02/15/2000 | CA2180621C New aminophenylphosphonic acid derivatives; process for preparing the same and pharmaceutical compositions containing them |
| 02/15/2000 | CA2154730C Synergetic blend compositions between at least one rxr specific ligand and at least one rar- specific ligand; uses thereof |
| 02/15/2000 | CA2132001C Methods of treating cancer using modified c-reactive protein |
| 02/15/2000 | CA2093667C Mouse monoclonal antibodies and uses thereof |
| 02/12/2000 | CA2248989A1 Novel compounds |
| 02/10/2000 | WO2000006759A2 Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same |
| 02/10/2000 | WO2000006758A1 Self-deleting vectors for cancer therapy |
| 02/10/2000 | WO2000006730A2 Human cytoskeletal proteins |
| 02/10/2000 | WO2000006729A1 Kdel receptor inhibitors |
| 02/10/2000 | WO2000006703A2 Inhibition of graft versus host disease |
| 02/10/2000 | WO2000006702A1 Cancer cells from body fluids containing cells, isolation thereof and agents containing the same |
| 02/10/2000 | WO2000006698A1 98 human secreted proteins |
| 02/10/2000 | WO2000006605A2 Heterominibodies |
| 02/10/2000 | WO2000006601A1 Isoforms of human calcium sensing receptor |
| 02/10/2000 | WO2000006598A1 Endogenous retrovirus tumor associated nucleic acids and antigens |
| 02/10/2000 | WO2000006589A1 Prostate derived ets factor |
| 02/10/2000 | WO2000006588A1 STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
| 02/10/2000 | WO2000006583A1 Tin polyoxaalkanecarboxylates and compositions containing them |
| 02/10/2000 | WO2000006577A1 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF |
| 02/10/2000 | WO2000006561A1 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
| 02/10/2000 | WO2000006555A1 Substituted quinazoline derivatives |
| 02/10/2000 | WO2000006542A1 Oxidised sulfurated distamycin derivatives, process for preparing them, and their use as antitumor agents |
| 02/10/2000 | WO2000006541A1 Sulfurated distamycin derivatives, process for preparing them, and their use as antitumor agents |
| 02/10/2000 | WO2000006206A1 Compositions and methods for the treatment and diagnosis of cardiovascular disease |
| 02/10/2000 | WO2000006205A1 Regulated expression of recombinant proteins using rna viruses |
| 02/10/2000 | WO2000006204A2 Genetically engineered cells and tissues |
| 02/10/2000 | WO2000006195A1 Targeting pharmaceutical agents to injured tissues |
| 02/10/2000 | WO2000006187A2 Modulation of apoptosis |
| 02/10/2000 | WO2000006185A2 Methods of using lanreotide, a somatostatin analogue |
| 02/10/2000 | WO2000006178A1 EX VIVO TREATMENT OF ALLOGENEIC AND XENOGENEIC T-CELLS WITH gp39 ANTAGONISTS |
| 02/10/2000 | WO2000006171A1 Antioxidant composition and method of treating diseases using same |
| 02/10/2000 | WO2000006169A1 Integrin receptor antagonists |
| 02/10/2000 | WO2000006167A1 Tricyclic compounds |
| 02/10/2000 | WO2000006140A2 Use of moclobemide for treating certain phsychiatric and medical disorders |
| 02/10/2000 | WO2000006134A2 Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity |
| 02/10/2000 | WO2000000825A3 Detection and modulation of cellular immunity to immune privileged antigens |
| 02/10/2000 | WO2000000510A8 Growth factor modulators |
| 02/10/2000 | WO1999062563A3 Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors |
| 02/10/2000 | WO1999062526A3 Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| 02/10/2000 | WO1999061600A3 A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 02/10/2000 | WO1999058678A3 Antibodies to dendritic cells and human dendritic cell populations and uses thereof |
| 02/10/2000 | WO1999058142A9 Use of anti-prolactin agents to treat proliferative conditions |
| 02/10/2000 | WO1999058139A3 Methods for detecting and inhibiting angiogenesis |
| 02/10/2000 | WO1999049038A3 Human calcium-binding proteins |
| 02/10/2000 | WO1999045126A3 Enhanced prodrug activation |
| 02/10/2000 | WO1999042481A3 AGENTS FOR TREATING HUMAN ILLNESSES BASED ON β-CATENIN, AND THE PRODUCTION AND USE THEREOF |
| 02/10/2000 | WO1999041376A3 Retinoblastoma protein complexes and retinoblastoma interacting proteins |
| 02/10/2000 | WO1999036105A3 USE OF RADIOLABELED MONOCLONAL IgM IN THERAPY FOR CANCER AND AUTOIMMUNE DISEASE |
| 02/10/2000 | WO1999023104A3 Antitumour uridine analogues |
| 02/10/2000 | DE19835611A1 Neuartige Phospholipide mit synthetischen, ungesättigten Alkyl- und Acylketten Novel synthetic phospholipids with unsaturated alkyl and acyl chains |
| 02/10/2000 | CA2339301A1 Hdpbo81 nucleic acids and polypeptides |
| 02/10/2000 | CA2339096A1 Modulation of apoptosis |
| 02/10/2000 | CA2338773A1 Ex vivo treatment of allogeneic and xenogeneic t-cells with gp39 antagonists |
| 02/10/2000 | CA2338330A1 Use of moclobemide for treating certain phsychiatric and medical disorders |
| 02/10/2000 | CA2338298A1 Tricyclic compounds |
| 02/10/2000 | CA2338275A1 Integrin receptor antagonists |
| 02/10/2000 | CA2338019A1 Prostate derived ets factor |
| 02/10/2000 | CA2337692A1 Kdel receptor inhibitors |
| 02/10/2000 | CA2337496A1 Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same |
| 02/10/2000 | CA2336802A1 Substituted quinazoline derivatives |
| 02/10/2000 | CA2336543A1 Isoforms of human calcium sensing receptor |
| 02/10/2000 | CA2336530A1 Compositions and methods for the treatment and diagnosis of cardiovascular disease |
| 02/10/2000 | CA2335656A1 Human cytoskeletal proteins |
| 02/10/2000 | CA2335654A1 Methods of using a somatostatin analogue |
| 02/10/2000 | CA2335077A1 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
| 02/10/2000 | CA2333854A1 Stereoisomers of cpg oligonucleotides and related methods |
| 02/09/2000 | EP0978561A1 Antisense oligonucleotides for the inhibition of VEGF expression |
| 02/09/2000 | EP0978559A2 Induction of tumour immunity by redirection of tumour cells against antigen presenting cells |
| 02/09/2000 | EP0977893A1 Reagents and methods useful for detecting diseases of the prostate |
| 02/09/2000 | EP0977892A1 Methods and compositions for use in modulating expression of matrix metalloproteinase genes |
| 02/09/2000 | EP0977862A2 Ricin-like toxin variants for treatment of cancer, viral or parasitic infections |
| 02/09/2000 | EP0977853A1 Secreted proteins and polynucleotides encoding them |